We claim:

1. A resiquimod monosulfate salt in crystal form.

2. The resiquimod monosulfate salt in crystal form of claim 1, wherein the resiquimod monosulfate salt in crystal form is an anhydrate.

3. The resiquimod monosulfate salt in crystal form of claim 1, wherein the resiquimod monosulfate salt in crystal form is characterized by

an x-ray powder diffraction spectrum that exhibits peaks at 7.6 ± 0.2° 2θ, 11.7 ± 0.2° 2θ, 15.5 ± 0.2° 2θ, 17.6 ± 0.2° 2θ, 18.2 ± 0.2° 2θ; and 24.4 ± 0.2° 2θ.

4. The resiquimod monosulfate salt in crystal form of claim 1, wherein the resiquimod monosulfate salt in crystal form is characterized by

an X-ray powder diffraction spectrum that exhibits peaks at 7.6 ± 0.2° 2θ, 9.6 ± 0.2° 2θ, 11.7 ± 0.2° 2θ, 13.4 ± 0.2° 2θ, 15.5 ± 0.2° 2θ, 17.6 ± 0.2° 2θ, 18.2 ± 0.2° 2θ; 23.5 ± 0.2° 2θ, and 24.4 ± 0.2° 2θ

5. The resiquimod monosulfate salt in crystal form of claim 1, wherein the resiquimod monosulfate salt in crystal form is characterized by

a DSC curve that exhibits a melting peak having an onset temperature between 209°C and 215°C.

6. The resiquimod monosulfate salt in crystal form of claim 1, wherein the resiquimod monosulfate salt in crystal form is characterized by

a DSC curve that exhibits a melting peak having an onset temperature at about 210° C and an endothermic peak at about 213° C

7. The resiquimod monosulfate salt in crystal form of claim 1, wherein the resiquimod monosulfate salt in crystal form is characterized by:

an X-ray powder diffraction spectrum that exhibits peaks at 7.6 ± 0.2° 2θ, 11.7 ± 0.2° 2θ, 15.5 ± 0.2° 2θ, 17.6 ± 0.2° 2θ, 18.2 ± 0.2° 2θ; and 24.4 ± 0.2° 2θ and

a DSC curve that exhibits a melting peak having an onset temperature between 209°C and 215°C.

8. The resiquimod monosulfate salt in crystal form of claim 1, wherein the resiquimod monosulfate salt in crystal form form is characterized by:

an X-ray powder diffraction spectrum that exhibits peaks at 7.6 ± 0.2° 2θ, 9.6 ± 0.2° 2θ, 11.7 ± 0.2° 2θ, 13.4 ± 0.2° 2θ, 15.5 ± 0.2° 2θ, 17.6 ± 0.2° 2θ, 18.2 ± 0.2° 2θ; 23.5 ± 0.2° 2θ, and 24.4 ± 0.2° 2θ and

a DSC curve that exhibits a melting peak having an onset temperature between 209°C and 215°C

9. A composition comprising the resiquimod monosulfate salt in crystal form of any one of claims 1-8 and at least one pharmaceutically acceptable carrier or excipient.

10. A method for preparing a pharmaceutical composition comprising combining the resiquimod monosulfate salt in crystal form of any one of claims 1-8 with a pharmaceutically acceptable excipient or carrier.

11. A pharmaceutical composition prepared by the method of claim 10.

12. A dosage form comprising the composition of claim 9.

13. Use of the resiquimod monosulfate salt in crystal form of any one of claims 1-8 in the manufacture of a medicament for treating cancer .

14. The use of claim 13, wherein the cancer is selected from breast cancer, head and neck cancer, ovarian cancer, uterine cancer, skin cancer, brain cancer, bladder cancer, thyroid cancer, liver cancer, pancreatic cancer, lung cancer, ocular cancer, throat cancer, esophageal cancer, stomach cancer, intestinal cancer, rectal cancer, testicular cancer, ovarian cancer, vaginal cancer, bone cancer, blood cancer, and prostate cancer.

15. Use of the resiquimod monosulfate salt in crystal form of any one of claims 1-8 in the manufacture of a medicament for treating a tumor.

16. The use of claim 15, wherein the tumor is a carcinoma, a sarcoma, or a blastoma, or a combination thereof.

17. The use of claim 16, wherein:

the tumor is a carcinoma selected from an adrenal gland tumor, a bone tumor, a brain tumor, a breast tumor, a bronchi tumor, a colon tumor, a gallbladder tumor, a kidney tumor, a larynx tumor, a liver tumor, a lung tumor, a neural tumor, a pancreatic tumor, a prostate tumor, a parathyroid tumor, a skin tumor, a stomach tumor, a thyroid tumor, an

adenocarcinoma, an adenosquamous carcinoma, an anaplastic carcinoma, a large cell carcinoma, a small cell carcinoma, a squamous cell carcinoma, a small cell carcinoma, a combined small cell carcinoma, a verrucous carcinoma, a basal cell carcinoma, a transitional cell carcinoma, an inverted papilloma, a linitis plastica, a familial adenomatous polyposis, an insulinoma, a glucagonoma, a gastrinoma, a VIPoma, a somatostatinoma, a cholangiocarcinoma, a Klatskin tumor, a hepatocellular adenoma, a hepatocellular carcinoma, a renal cell carcinoma, an endometrioid tumor, a renal oncocytoma, a prolactinoma, a multiple endocrine neoplasia, an adrenocortical adenoma, an adrenocortical carcinoma, a Hurthle cell, a neuroendocrine tumor, an adenoid cystic carcinoma, an oncocytoma, a clear cell adenocarcinoma, an apudoma, a cylindroma, a papillary hidradenoma, a hidrocystoma, a syringoma, a syringocystadenoma papilliferum, a cystadenoma, a cystadenocarcinoma, a signet ring cell carcinoma, a mucinous cystadenoma, a mucinous cystadenocarcinoma, a mucoepidermoid carcinoma, an ovarian serous cystadenoma, a pancreatic serous cystadenoma, a serous cystadenocarcinoma, a papillary serous cystadenocarcinoma, a mammary ductal carcinoma, a pancreatic ductal carcinoma, a comedocarcinoma, a Paget's disease of the breast, an extramammary Paget's disease, a lobular carcinoma in situ, an invasive lobular carcinoma, a medullary carcinoma of the breast, a medullary thyroid cancer, an acinic cell carcinoma, a Warthin's tumor, and a thymoma, or

the tumor is a sarcoma selected from a soft tissue sarcoma, a connective tissue sarcoma, a lipomatous sarcoma, a myomatous sarcoma, a complex mixed and stromal sarcoma, an adenomatoid tumor, an adenomyoma, an aggressive infantile fibromatosis, an alveolar rhabdomyosarcoma, an angiolipoleiomyoma, an angiomyolipoma, an angioleiomyoma, an angiomyxoma, an angiosarcoma, an aponeurotic fibroma, an Askin's tumor, an atypical fibroxanthoma, a benign lipoblastomatosis, a Brenner tumor, a carcinosarcoma, a chondroid lipoma, a chondrosarcoma, a clear-cell sarcoma, a clear-cell sarcoma of the kidney, a collagenous fibroma, a cystosarcoma phyllodes, a dermatofibrosarcoma, a dermatofibrosarcoma protuberans (DFSP) , a desmoplastic fibroma, a desmoplastic small round cell tumor, a diffuse infantile fibromatosis, a Ewing's /PNET sarcoma, a familial myxovascular fibroma, a fibroadenoma, a fibroma of tendon sheath, a fibromatosis colli, a fibrous histiocytoma, a fibrosarcoma, a gastrointestinal stromal tumor (GIST) , a genital leiomyoma, a hemangioendothelioma, a hepatoblastoma, a hibernoma, a histiocytoma, an infantile digital fibromatosis, an intradermal spindle cell lipoma, a juvenile hyaline fibromatosis, a Kaposi's sarcoma, a leiomyosarcoma, a liposarcoma, a mesoblastic nephroma, a mesothelioma, a mixed Müllerian tumor, a multiple cutaneous leiomyoma, a multiple cutaneous and uterine leiomyomatosis syndrome, a myelolipoma, a myosarcoma, a myxoid liposarcoma, a myxosarcoma, a neural fibrolipoma, a neurofibrosarcoma, an oral

submucous fibrosis, an ossifying fibromyxoid tumor, an osteosarcoma, a pancreatoblastoma, a phyllodes tumor, a plantar fibromatosis, a pleomorphic adenoma, a pleomorphic fibroma, a pleomorphic lipoma, a rhabdomyosarcoma, a sarcoma botryoides, a schwannoma sarcoma, a solitary cutaneous leiomyoma, a solitary fibrous tumor, a spindle cell lipoma, a stromal tumor of undetermined malignant potential (STUMP) , a synovial sarcoma, a vascular sarcoma, and a Wilms' tumor, or

the tumor is a blastoma selected from a chondroblastoma, a hepatoblastoma, a medulloblastoma, a nephroblastoma, a neuroblastoma, a pancreatoblastoma, a pleuropulmonary blastoma, a retinoblastoma, and a glioblastoma multiforme.

18. Use of the composition of claim 9 in the manufacture of a medicament for treating cancer.

19. The use of claim 18, wherein the cancer is selected from breast cancer, head and neck cancer, ovarian cancer, uterine cancer, skin cancer, brain cancer, bladder cancer, thyroid cancer, liver cancer, pancreatic cancer, lung cancer, ocular cancer, throat cancer, esophageal cancer, stomach cancer, intestinal cancer, rectal cancer, testicular cancer, ovarian cancer, vaginal cancer, bone cancer, blood cancer, and prostate cancer.

20. Use of the composition of claim 9 in the manufacture of a medicament for treating a tumor.

21. The use of claim 20, wherein the tumor is a carcinoma, a sarcoma, or a blastoma, or a combination thereof.

22. The use of claim 21, wherein:

the tumor is a carcinoma selected from an adrenal gland tumor, a bone tumor, a brain tumor, a breast tumor, a bronchi tumor, a colon tumor, a gallbladder tumor, a kidney tumor, a larynx tumor, a liver tumor, a lung tumor, a neural tumor, a pancreatic tumor, a prostate tumor, a parathyroid tumor, a skin tumor, a stomach tumor, a thyroid tumor, an adenocarcinoma, an adenosquamous carcinoma, an anaplastic carcinoma, a large cell carcinoma, a small cell carcinoma, a squamous cell carcinoma, a small cell carcinoma, a combined small cell carcinoma, a verrucous carcinoma, a basal cell carcinoma, a transitional cell carcinoma, an inverted papilloma, a linitis plastica, a familial adenomatous polyposis, an insulinoma, a glucagonoma, a gastrinoma, a VIPoma, a somatostatinoma, a cholangiocarcinoma, a Klatskin tumor, a hepatocellular adenoma, a hepatocellular carcinoma, a renal cell carcinoma, an endometrioid tumor, a renal oncocytoma, a

prolactinoma, a multiple endocrine neoplasia, an adrenocortical adenoma, an adrenocortical carcinoma, a Hurthle cell, a neuroendocrine tumor, an adenoid cystic carcinoma, an oncocytoma, a clear cell adenocarcinoma, an apudoma, a cylindroma, a papillary hidradenoma, a hidrocystoma, a syringoma, a syringocystadenoma papilliferum, a cystadenoma, a cystadenocarcinoma, a signet ring cell carcinoma, a mucinous cystadenoma, a mucinous cystadenocarcinoma, a mucoepidermoid carcinoma, an ovarian serous cystadenoma, a pancreatic serous cystadenoma, a serous cystadenocarcinoma, a papillary serous cystadenocarcinoma, a mammary ductal carcinoma, a pancreatic ductal carcinoma, a comedocarcinoma, a Paget's disease of the breast, an extramammary Paget's disease, a lobular carcinoma in situ, an invasive lobular carcinoma, a medullary carcinoma of the breast, a medullary thyroid cancer, an acinic cell carcinoma, a Warthin's tumor, and a thymoma, or

the tumor is a sarcoma selected from a soft tissue sarcoma, a connective tissue sarcoma, a lipomatous sarcoma, a myomatous sarcoma, a complex mixed and stromal sarcoma, an adenomatoid tumor, an adenomyoma, an aggressive infantile fibromatosis, an alveolar rhabdomyosarcoma, an angiolipoleiomyoma, an angiomyolipoma, an angioleiomyoma, an angiomyxoma, an angiosarcoma, an aponeurotic fibroma, an Askin's tumor, an atypical fibroxanthoma, a benign lipoblastomatosis, a Brenner tumor, a carcinosarcoma, a chondroid lipoma, a chondrosarcoma, a clear-cell sarcoma, a clear-cell sarcoma of the kidney, a collagenous fibroma, a cystosarcoma phyllodes, a dermatofibrosarcoma, a dermatofibrosarcoma protuberans (DFSP) , a desmoplastic fibroma, a desmoplastic small round cell tumor, a diffuse infantile fibromatosis, a Ewing's /PNET sarcoma, a familial myxovascular fibroma, a fibroadenoma, a fibroma of tendon sheath, a fibromatosis colli, a fibrous histiocytoma, a fibrosarcoma, a gastrointestinal stromal tumor (GIST) , a genital leiomyoma, a hemangioendothelioma, a hepatoblastoma, a hibernoma, a histiocytoma, an infantile digital fibromatosis, an intradermal spindle cell lipoma, a juvenile hyaline fibromatosis, a Kaposi's sarcoma, a leiomyosarcoma, a liposarcoma, a mesoblastic nephroma, a mesothelioma, a mixed Müllerian tumor, a multiple cutaneous leiomyoma, a multiple cutaneous and uterine leiomyomatosis syndrome, a myelolipoma, a myosarcoma, a myxoid liposarcoma, a myxosarcoma, a neural fibrolipoma, a neurofibrosarcoma, an oral submucous fibrosis, an ossifying fibromyxoid tumor, an osteosarcoma, a pancreatoblastoma, a phyllodes tumor, a plantar fibromatosis, a pleomorphic adenoma, a pleomorphic fibroma, a pleomorphic lipoma, a rhabdomyosarcoma, a sarcoma botryoides, a schwannoma sarcoma, a solitary cutaneous leiomyoma, a solitary fibrous tumor, a spindle cell lipoma, a stromal tumor of undetermined malignant potential (STUMP) , a synovial sarcoma, a vascular sarcoma, and a Wilms' tumor, or

the tumor is a blastoma selected from a chondroblastoma, a hepatoblastoma, a medulloblastoma, a nephroblastoma, a neuroblastoma, a pancreatoblastoma, a pleuropulmonary blastoma, a retinoblastoma, and a glioblastoma multiforme.

23. Use of the pharmaceutical composition of claim 11 in the manufacture of a medicament for treating cancer.

24. The use of claim 23, wherein the cancer is selected from breast cancer, head and neck cancer, ovarian cancer, uterine cancer, skin cancer, brain cancer, bladder cancer, thyroid cancer, liver cancer, pancreatic cancer, lung cancer, ocular cancer, throat cancer, esophageal cancer, stomach cancer, intestinal cancer, rectal cancer, testicular cancer, ovarian cancer, vaginal cancer, bone cancer, blood cancer, and prostate cancer.

25. Use of the pharmaceutical composition of claim 11 for use in treating a tumor.

26. The use of claim 25, wherein the tumor is a carcinoma, a sarcoma, or a blastoma, or a combination thereof.

27. The use of claim 26, wherein:

the tumor is a carcinoma selected from an adrenal gland tumor, a bone tumor, a brain tumor, a breast tumor, a bronchi tumor, a colon tumor, a gallbladder tumor, a kidney tumor, a larynx tumor, a liver tumor, a lung tumor, a neural tumor, a pancreatic tumor, a prostate tumor, a parathyroid tumor, a skin tumor, a stomach tumor, a thyroid tumor, an adenocarcinoma, an adenosquamous carcinoma, an anaplastic carcinoma, a large cell carcinoma, a small cell carcinoma, a squamous cell carcinoma, a small cell carcinoma, a combined small cell carcinoma, a verrucous carcinoma, a basal cell carcinoma, a transitional cell carcinoma, an inverted papilloma, a linitis plastica, a familial adenomatous polyposis, an insulinoma, a glucagonoma, a gastrinoma, a VIPoma, a somatostatinoma, a cholangiocarcinoma, a Klatskin tumor, a hepatocellular adenoma, a hepatocellular carcinoma, a renal cell carcinoma, an endometrioid tumor, a renal oncocytoma, a prolactinoma, a multiple endocrine neoplasia, an adrenocortical adenoma, an adrenocortical carcinoma, a Hurthle cell, a neuroendocrine tumor, an adenoid cystic carcinoma, an oncocytoma, a clear cell adenocarcinoma, an apudoma, a cylindroma, a papillary hidradenoma, a hidrocystoma, a syringoma, a syringocystadenoma papilliferum, a cystadenoma, a cystadenocarcinoma, a signet ring cell carcinoma, a mucinous cystadenoma, a mucinous cystadenocarcinoma, a mucoepidermoid carcinoma, an ovarian serous cystadenoma, a pancreatic serous cystadenoma, a serous cystadenocarcinoma, a

papillary serous cystadenocarcinoma, a mammary ductal carcinoma, a pancreatic ductal carcinoma, a comedocarcinoma, a Paget's disease of the breast, an extramammary Paget's disease, a lobular carcinoma in situ, an invasive lobular carcinoma, a medullary carcinoma of the breast, a medullary thyroid cancer, an acinic cell carcinoma, a Warthin's tumor, and a thymoma, or

the tumor is a sarcoma selected from a soft tissue sarcoma, a connective tissue sarcoma, a lipomatous sarcoma, a myomatous sarcoma, a complex mixed and stromal sarcoma, an adenomatoid tumor, an adenomyoma, an aggressive infantile fibromatosis, an alveolar rhabdomyosarcoma, an angiolipoleiomyoma, an angiomyolipoma, an angioleiomyoma, an angiomyxoma, an angiosarcoma, an aponeurotic fibroma, an Askin's tumor, an atypical fibroxanthoma, a benign lipoblastomatosis, a Brenner tumor, a carcinosarcoma, a chondroid lipoma, a chondrosarcoma, a clear-cell sarcoma, a clear-cell sarcoma of the kidney, a collagenous fibroma, a cystosarcoma phyllodes, a dermatofibrosarcoma, a dermatofibrosarcoma protuberans (DFSP) , a desmoplastic fibroma, a desmoplastic small round cell tumor, a diffuse infantile fibromatosis, a Ewing's /PNET sarcoma, a familial myxovascular fibroma, a fibroadenoma, a fibroma of tendon sheath, a fibromatosis colli, a fibrous histiocytoma, a fibrosarcoma, a gastrointestinal stromal tumor (GIST) , a genital leiomyoma, a hemangioendothelioma, a hepatoblastoma, a hibernoma, a histiocytoma, an infantile digital fibromatosis, an intradermal spindle cell lipoma, a juvenile hyaline fibromatosis, a Kaposi's sarcoma, a leiomyosarcoma, a liposarcoma, a mesoblastic nephroma, a mesothelioma, a mixed Müllerian tumor, a multiple cutaneous leiomyoma, a multiple cutaneous and uterine leiomyomatosis syndrome, a myelolipoma, a myosarcoma, a myxoid liposarcoma, a myxosarcoma, a neural fibrolipoma, a neurofibrosarcoma, an oral submucous fibrosis, an ossifying fibromyxoid tumor, an osteosarcoma, a pancreatoblastoma, a phyllodes tumor, a plantar fibromatosis, a pleomorphic adenoma, a pleomorphic fibroma, a pleomorphic lipoma, a rhabdomyosarcoma, a sarcoma botryoides, a schwannoma sarcoma, a solitary cutaneous leiomyoma, a solitary fibrous tumor, a spindle cell lipoma, a stromal tumor of undetermined malignant potential (STUMP) , a synovial sarcoma, a vascular sarcoma, and a Wilms' tumor, or

the tumor is a blastoma selected from a chondroblastoma, a hepatoblastoma, a medulloblastoma, a nephroblastoma, a neuroblastoma, a pancreatoblastoma, a pleuropulmonary blastoma, a retinoblastoma, and a glioblastoma multiforme.

28. Use of the dosage form of claim 12 in the manufacture of a medicament for treating cancer.

29. The use of claim 28, wherein the cancer is selected from breast cancer, head and neck cancer, ovarian cancer, uterine cancer, skin cancer, brain cancer, bladder cancer, thyroid cancer, liver cancer, pancreatic cancer, lung cancer, ocular cancer, throat cancer, esophageal cancer, stomach cancer, intestinal cancer, rectal cancer, testicular cancer, ovarian cancer, vaginal cancer, bone cancer, blood cancer, and prostate cancer.

30. Use of the dosage form of claim 12 in the manufacture of a medicament for treating a tumor.

31. The use of claim 30, wherein the tumor is a carcinoma, a sarcoma, or a blastoma, or a combination thereof.

32. The use of claim 31, wherein:

the tumor is a carcinoma selected from an adrenal gland tumor, a bone tumor, a brain tumor, a breast tumor, a bronchi tumor, a colon tumor, a gallbladder tumor, a kidney tumor, a larynx tumor, a liver tumor, a lung tumor, a neural tumor, a pancreatic tumor, a prostate tumor, a parathyroid tumor, a skin tumor, a stomach tumor, a thyroid tumor, an adenocarcinoma, an adenosquamous carcinoma, an anaplastic carcinoma, a large cell carcinoma, a small cell carcinoma, a squamous cell carcinoma, a small cell carcinoma, a combined small cell carcinoma, a verrucous carcinoma, a basal cell carcinoma, a transitional cell carcinoma, an inverted papilloma, a linitis plastica, a familial adenomatous polyposis, an insulinoma, a glucagonoma, a gastrinoma, a VIPoma, a somatostatinoma, a cholangiocarcinoma, a Klatskin tumor, a hepatocellular adenoma, a hepatocellular carcinoma, a renal cell carcinoma, an endometrioid tumor, a renal oncocytoma, a prolactinoma, a multiple endocrine neoplasia, an adrenocortical adenoma, an adrenocortical carcinoma, a Hurthle cell, a neuroendocrine tumor, an adenoid cystic carcinoma, an oncocytoma, a clear cell adenocarcinoma, an apudoma, a cylindroma, a papillary hidradenoma, a hidrocystoma, a syringoma, a syringocystadenoma papilliferum, a cystadenoma, a cystadenocarcinoma, a signet ring cell carcinoma, a mucinous cystadenoma, a mucinous cystadenocarcinoma, a mucoepidermoid carcinoma, an ovarian serous cystadenoma, a pancreatic serous cystadenoma, a serous cystadenocarcinoma, a papillary serous cystadenocarcinoma, a mammary ductal carcinoma, a pancreatic ductal carcinoma, a comedocarcinoma, a Paget's disease of the breast, an extramammary Paget's disease, a lobular carcinoma in situ, an invasive lobular carcinoma, a medullary carcinoma of the breast, a medullary thyroid cancer, an acinic cell carcinoma, a Warthin's tumor, and a thymoma, or

the tumor is a sarcoma selected from a soft tissue sarcoma, a connective tissue sarcoma, a lipomatous sarcoma, a myomatous sarcoma, a complex mixed and stromal sarcoma, an adenomatoid tumor, an adenomyoma, an aggressive infantile fibromatosis, an alveolar rhabdomyosarcoma, an angiolipoleiomyoma, an angiomyolipoma, an angioleiomyoma, an angiomyxoma, an angiosarcoma, an aponeurotic fibroma, an Askin's tumor, an atypical fibroxanthoma, a benign lipoblastomatosis, a Brenner tumor, a carcinosarcoma, a chondroid lipoma, a chondrosarcoma, a clear-cell sarcoma, a clear-cell sarcoma of the kidney, a collagenous fibroma, a cystosarcoma phyllodes, a dermatofibrosarcoma, a dermatofibrosarcoma protuberans (DFSP) , a desmoplastic fibroma, a desmoplastic small round cell tumor, a diffuse infantile fibromatosis, a Ewing's /PNET sarcoma, a familial myxovascular fibroma, a fibroadenoma, a fibroma of tendon sheath, a fibromatosis colli, a fibrous histiocytoma, a fibrosarcoma, a gastrointestinal stromal tumor (GIST) , a genital leiomyoma, a hemangioendothelioma, a hepatoblastoma, a hibernoma, a histiocytoma, an infantile digital fibromatosis, an intradermal spindle cell lipoma, a juvenile hyaline fibromatosis, a Kaposi's sarcoma, a leiomyosarcoma, a liposarcoma, a mesoblastic nephroma, a mesothelioma, a mixed Müllerian tumor, a multiple cutaneous leiomyoma, a multiple cutaneous and uterine leiomyomatosis syndrome, a myelolipoma, a myosarcoma, a myxoid liposarcoma, a myxosarcoma, a neural fibrolipoma, a neurofibrosarcoma, an oral submucous fibrosis, an ossifying fibromyxoid tumor, an osteosarcoma, a pancreatoblastoma, a phyllodes tumor, a plantar fibromatosis, a pleomorphic adenoma, a pleomorphic fibroma, a pleomorphic lipoma, a rhabdomyosarcoma, a sarcoma botryoides, a schwannoma sarcoma, a solitary cutaneous leiomyoma, a solitary fibrous tumor, a spindle cell lipoma, a stromal tumor of undetermined malignant potential (STUMP) , a synovial sarcoma, a vascular sarcoma, and a Wilms’ tumor, or

the tumor is a blastoma selected from a chondroblastoma, a hepatoblastoma, a medulloblastoma, a nephroblastoma, a neuroblastoma, a pancreatoblastoma, a pleuropulmonary blastoma, a retinoblastoma, and a glioblastoma multiforme.